FLT1 and glioblastoma: Furthermore, in agreement with our results, in patients with recurrent glioblastoma treated with aflibercept, an anti-angiogenic molecule that binds to VEGF and PlGF, a decrease of VEGFR-1+ monocytes from baseline to 24 h was associated with improved objective response [43].